Novocure announced that Optune Lua® has received a Conformité Européenne (CE) Mark for the treatment of adult patients with metastatic non-small cell lung cancer concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen.
[Novocure]
